The nanosystem consists of three components, liposome that acts as carrier to loading the inhibitor; 3-bromopyruvate which serves as specific inhibitor of HK II to inhibit glycolysis, and CREKA is employed as recognition components for target the tumor vascular endothelium. Here, HK2 is linked to neoplasm.